Study of Rivaroxaban for CeREbral Venous Thrombosis

Phase 2 Completed 55 enrolled University of British Columbia

RandomizedParallel-groupSingle-blindTreatment

Summary

SECRET examines the safety of rivaroxaban versus standard-of-care for treatment of symptomatic cerebral venous thrombosis, initiated within 14 days of diagnosis.

Timeline

Start: 2019-03-12
Primary completion: 2022-10-05
Completion: 2022-10-05

Publications

Field TS, Dizonno V, Almekhlafi MA, Bala F, Alhabli I, Wong H, Norena M, Villaluna MK, King-Azote P, Ratnaweera N, Mancini S, Van Gaal SC, Wilson LK, Graham BR, Sposato LA, Blacquiere D, Dewar BM, Boulos MI, Buck BH, Odier C, Perera KS, Pikula A, Tkach A, Medvedev G, Canfield C, Mortenson WB, Nadeau JO, Alshimemeri S, Benavente OR, Demchuk AM, Dowlatshahi D, Lanthier S, Lee AYY, Mandzia J, Suryanarayan D, Weitz JI, Hill MD; SECRET Investigators. Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis. Stroke. 2023 Nov;54(11):2724-2736. doi: 10.1161/STROKEAHA.123.044113. Epub 2023 Sep 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivaroxaban	Other / unclassified	15 mg	Oral
Subject	Rivaroxaban	Other / unclassified	20 mg	Oral
Comparator	Dalteparin sodium	Other / unclassified	—	—
Comparator	Enoxaparin sodium	Other / unclassified	—	—
Comparator	Heparin	Other / unclassified	—	—
Comparator	Standard of care	Unknown	—	—
Comparator	Tinzaparin	Other / unclassified	—	—

Study of Rivaroxaban for CeREbral Venous Thrombosis

Summary

Timeline

Publications

Drugs

Indications